Vanguard Group Inc Annovis Bio, Inc. Call Options Transaction History
Vanguard Group Inc
- $6.44 Trillion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ANVS
# of Institutions
49Shares Held
2.03MCall Options Held
167KPut Options Held
97.2K-
Susquehanna International Group, LLP Bala Cynwyd, PA218KShares$504,5520.0% of portfolio
-
Geode Capital Management, LLC Boston, MA184KShares$425,3950.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il174KShares$402,7360.0% of portfolio
-
Northern Trust Corp Chicago, IL121KShares$279,6480.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$232,6370.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $18.9M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...